Aarti Drugs profit and loss

Latest FY26
Revenue
₹2,565cr+7.5% on FY25
EBITDA
₹309cr+7.7% on FY25
Net profit
₹195cr+16.0% on FY25
EPS
₹21.36+16.4% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
2,6782,5652,3872,5292,716
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.92.416.44.02.2
2,6802,5682,4032,5332,718
Expenses
1,6161,5041,4381,5721,769
10811584.380.2121
−51.0−0.419.525.5−1.8
13512911210292.0
34.433.735.933.533.3
70.767.055.851.550.3
536508446432430
2,4492,3572,1922,2972,494
333309287316306
263242231265255
Profit
231211212236224
−2.10.00.00.00.0
229211212236224
35.913.341.259.658.9
2.12.72.54.4−1.0
37.916.043.763.957.8
191195168172166
191195168172166
3.13.21.60.1−1.5
194198170172165
191195168171166
−0.10.0−0.10.20.1
Per share
₹20.93₹21.36₹18.35₹18.56₹17.97
₹20.93₹21.36₹18.35₹18.56₹17.97
Other comprehensive income — detail
3.13.21.6——
3.13.21.60.1—
194198170172165
−0.10.0−0.00.10.1
Per share — as-filed variants
₹20.93₹21.36₹18.35₹18.56₹17.97
₹20.93₹21.36₹18.35₹18.56₹17.97
Derived — gross profit (revenue − materials − purchases − Δ inventories)
1,005947845851828
37.5%36.9%35.4%33.6%30.5%
Adjusted (ex-exceptional items) — derived
231211212236224
−2.10.00.00.00.0
193195168172166
₹21.12₹21.36₹18.35₹18.56₹17.97
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AARTIDRUGS₹449.00

Aarti Drugs Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersALIVUSAARTIPHARMADVENZYMESAGARWALEYEAKUMSAPLLTDCORONAHCGMcap ₹4,098 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations2,716.12,528.62,387.02,565.32,677.6
Other Income2.24.016.42.42.9
Total Income2,718.22,532.62,403.42,567.72,680.5
Expenses
+ Cost of Materials Consumed1,769.01,572.01,438.31,504.01,616.1
+ Purchases of Stock-in-Trade121.380.284.3115.1107.9
+ Changes in Inventories-1.825.519.5-0.4-51.0
+ Employee Benefit Expense92.0102.3112.1129.3135.0
+ Finance Costs33.333.535.933.734.4
+ Depreciation & Amortisation50.351.555.867.070.7
+ Other Expenses429.9432.1445.8508.1536.3
Total Expenses2,494.12,297.12,191.62,356.82,449.4
EBITDA305.6316.5287.1309.2333.3
EBIT255.3265.0231.3242.2262.6
Profit
PBT before Exceptional Items224.2235.5211.8210.9231.1
+ Exceptional Items0.00.00.00.0-2.1
Pretax Income224.2235.5211.8210.9229.0
+ Current Tax58.959.641.213.335.9
+ Deferred Tax-1.04.42.52.72.1
Tax Expense57.863.943.716.037.9
Net Income166.4171.6168.1194.9191.1
+ Net Income — Continuing Ops166.4171.6168.1194.9191.1
+ Other Comprehensive Income-1.50.11.63.23.1
Total Comprehensive Income164.9171.7169.7198.1194.2
Net Income to Common166.3171.4168.2194.9191.2
Minority Interest0.10.2-0.10.0-0.1
Per Share
Basic EPS17.9718.5618.3521.3620.93
Diluted EPS17.9718.5618.3521.3620.93
Other Comprehensive Income — detail
+ Other Comprehensive Income——1.63.23.1
+ Items NOT to be Reclassified to P&L—0.11.63.23.1
Comprehensive Income — Owners of Parent164.8171.5169.7198.1194.3
Comprehensive Income — Non-controlling Interests0.10.1-0.00.0-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations17.9718.5618.3521.3620.93
Diluted EPS — Continuing Operations17.9718.5618.3521.3620.93
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit827.5850.9844.9946.61,004.6
Gross Margin %30.4733.6535.4036.9037.52
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)224.2235.5211.8210.9231.1
− Exceptional Items (reconciliation)0.00.00.00.0-2.1
Net Income Adj (tax-effected)166.4171.6168.1194.9192.8
EPS Adj17.9718.5618.3521.3621.12
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.00
Paid Up Equity Capital92.691.991.391.391.3
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.